Other References: Wilens et al. (The Psychiatric Clinics of North America: Pediatric Psychopharmacology; Mar. 1992; 15(1):191-222). cited by examiner
Gabbard, Glen O. Gabbard's treatments of psychiatric disorders. American Psychiatric Publishing Inc. Arlington, VA. 2007. cited by examiner
D.J. Begley (Pharmacology & Therapeutics 104 (2004) 29-45). cited by examiner
Hans et al., “Nanoparticles for drug delivery.” Handbook of Nanoscience, Engineering, and Technology. Second Edition. Gerald. Boca Raton, FL; Taylor & Francis Group, 2007. cited by examiner
Posey et al. (CNS Drug Reviews; “Guanfacine and Guanfacine Extended Release:Treatment for ADHD and Related Disorders.” CNS Drug Rev. 2007 Winter;13(4):465-74). (Year: 2007). cited by examiner
Agarwal et al.; 2008; “Combination of Atomoxetine and Methylphenidate in Attention Deficit/Hyperactivity Disorder: A Case Report.” J Can Acad Child Adolesc Psychiatry, 17(3): 160. cited by applicant
clincaltrials.gov; 2008; “Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder”; National Institute of Mental Health (NIMH); retrieved Apr. 19, 2010 from http://clinicaltrials.gov/ct2/show/NCT00429273. cited by applicant
Jay; 2010; “Combination Therapy with Shire's Intuniv Shown Safe for Non-responsive ADHD Patients or Those with Sleep Problems”; Mental Health Behavioral Health Medical Professionals Resources; retrieved Apr. 19, 2010 from http://www.behavioralhealthcentral.com/index.php/20100120187285/Sleep-latest/combination-t. cited by applicant
Shire Press Release; 2009; “Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV™ (guanfacine) Extended-Release Tablets with Stimulants”. cited by applicant
Sallee; 2008; “The Role of Alpha 2 Agonists in the Attention Deficit/Hyperactivity Disorder Treatment Paradigm”; Medscape Psychiatry & Mental Health; retrieved Apr. 19, 2010 from http://cme.medscape.com/viewarticle/577743. cited by applicant
Spencer et al.; 2009; “Safety and Effectiveness of Coadministration of Guanfacine Extended Release and Psychostimulants in Children and Adolescents with Attention-Deficit=Hyperactivity Disorder”; Journal of Child and Adolescent Psychopharmacology; 19(5): 501-510. cited by applicant
Ravikumar et al.; 2009; “Formation of Nanoparticles of Water-soluble Molecules through Evaporation of Water-in-Oil Microemulsions”; RSS 2009, Dept. of Chemical Engg, IIT Bombay; Oral Presentations. cited by applicant
Bawa; 2008; “Nanoparticle-based Therapeutics in Humans: A Survey”; Nanotechnology Law & Business. cited by applicant
Castellanos FX et al. “Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose.” J Am Acad Child Adolesc Psychiatry. May 1997; 36(5):589-96. cited by applicant
Bloch et al., “Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders.” J Am Acad Child Adolesc Psychiatry. Sep. 2009;48(9):884-93. cited by applicant
Scahill et al., “A Placebo-Controlled Study of Guanfacine in the Treatment of Children with Tic Discorders and Attention Deficit Hyperactivity Disorder.” Am J. Psychiatry 2001, 158:1067-1074. cited by applicant
Dextroamphetamine Compound Summary—PubChem—CID #5826, Sep. 16, 2004, pp. 1-14. cited by applicant
Dexedrine FDA Label, Prescribing Information, GlaxoSmithKline 2007, pp. 1-11. cited by applicant
Adderall FDA Label, DSM Pharmaceuticals Inc., Mar. 2007, pp. 1-15. cited by applicant
The Tourette's Syndrome Study Group “Treatment of ADHD in children with tics: A randomized controlled trial” Neurology 2002; 58:527-536. cited by applicant
Kurlan et al., “Clonidine and methylphenidate were effective for attention deficit hyperactivity disorder in children with comorbid tics.” Evidence-based Medicine, Sep. 2002, 7(5): 157. cited by applicant
Hans, et al., “Biodegradable nanoparticles for drug delivery and targeting” Current Opinion in Solid State and Materials Science, 2002, 6:319-32. cited by applicant
Junghanns et al., “Nanocrystal technology, drug delivery and clinical applications.” Int J Nanomedicine. 2008;3(3):295-309. cited by applicant
Brown et al., “Atomoxetine and stimulants in combination for treatment of attention deficit hyperactivity disorder: four case reports.” J Child Adolesc Psychopharmacol. 2004 Spring;14(1):129-36. cited by applicant
Di and Kerns, “Drug-Like Properties: Concepts, structure, design and methods,” ISBN: 978-0-12-801076-1, Elsevier, chapters 8 and 9, (2016). cited by applicant
Advisory Action in U.S. Appl. No. 13/656,415 dated Sep. 22, 2015. cited by applicant
Office Action in U.S. Appl. No. 13/656,415 dated Mar. 28, 2014. cited by applicant
Office Action in U.S. Appl. No. 13/656,415 dated Jun. 24, 2015. cited by applicant
Office Action in U.S. Appl. No. 13/656,415 dated Sep. 5, 2013. cited by applicant
Office Action in U.S. Appl. No. 13/656,415 dated Jan. 7, 2015. cited by applicant
Notice of Allowance in U.S. Appl. No. 13/656,415 dated Sep. 23, 2016. cited by applicant
Office Action in U.S. Appl. No. 13/656,415 dated May 28, 2013. cited by applicant
Office Action in U.S. Appl. No. 15/339,453 dated Nov. 6, 2017. cited by applicant
Office Action in U.S. Appl. No. 15/339,453 dated Apr. 24, 2017. cited by applicant
European Patent Office, “Intention to Grant,” issued in connection with European Patent Application No. 11772852.7, dated Jan. 26, 2018. cited by applicant
No Comments.